^
Association details:
| Biomarker: | IL2 elevation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | everolimus (mTOR inhibitor) + lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
Published date:
07/24/2020
Excerpt:
PD assessment revealed significant association of cytokine levels (interleukin-2 (IL2), IL21 and IL17), baseline activated and total CD8+ lymphocytes and change in B cell lymphocytes and activated NK cells with clinical benefit.
DOI:
10.1038/s41416-020-0988-2
Trial ID:
